Objectives To update the evidence on efficacy of DMARDs (disease-modifying antirheumatic
drugs) and inform the taskforce of the 2022 update of the European Alliance of Associations …

The methods and results of systematic reviews should be reported in sufficient detail to allow
users to assess the trustworthiness and applicability of the review findings. The Preferred …

Chronic illnesses are associated with an increased risk of depression and anxiety.
Rheumatoid arthritis (RA) is a chronic autoimmune disease that typically causes damage to …

Rheumatoid arthritis (RA) management is driven by evidence, and new 2019 EULAR
recommendations help in refining the relevant place of different disease-modifying anti …

Background Early diagnosis and treatment of juvenile idiopathic arthritis (JIA) with
conventional and biologic disease-modifying anti-rheumatic drugs have vastly improved …

Objective To provide the initial installment of a living guideline that will provide up-to-date
guidance on the pharmacological management of patients with rheumatoid arthritis (RA) in …

Globally, healthcare systems are challenged with providing appropriate care to patients with
complex care needs, multiple chronic conditions (multimorbidity) and multiple medications …

Objective To systematically review possible predictors of successful discontinuation of
biologic or targeted synthetic DMARDs (b/tsDMARDs) in RA patients in remission or low …

Objective To develop and validate definitions for disease flares in rheumatoid arthritis (RA)
based on the quantitative Simplified and Clinical Disease Activity Indices (SDAI, CDAI) …

Objectives To develop evidence-based points to consider for cost-effective use of biological
and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the …